Réus Gislaine Z, Abelaira Helena M, Tuon Talita, Titus Stephanie E, Ignácio Zuleide M, Rodrigues Ana Lúcia S, Quevedo João
Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciuma, Santa Catarina, Brazil.
Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciuma, Santa Catarina, Brazil.
Adv Protein Chem Struct Biol. 2016;103:169-202. doi: 10.1016/bs.apcsb.2015.10.003. Epub 2015 Dec 17.
Major depressive disorder (MDD) affects approximately 121 million individuals globally and poses a significant burden to the healthcare system. Around 50-60% of patients with MDD respond adequately to existing treatments that are primarily based on a monoaminergic system. However, the neurobiology of MDD has not been fully elucidated; therefore, it is possible that other biochemical alterations are involved. The glutamatergic system and its associated receptors have been implicated in the pathophysiology of MDD. In fact, the N-methyl-d-aspartate (NMDA) receptor, a glutamate receptor, is a binding or modulation site for both classical antidepressants and new fast-acting antidepressants. Thus, this review aims to present evidence describing the effect of antidepressants that modulate NMDA receptors and the mechanisms that contribute to the antidepressant response.
重度抑郁症（MDD）在全球影响着约1.21亿人，给医疗系统带来了沉重负担。约50%-60%的MDD患者对主要基于单胺能系统的现有治疗有充分反应。然而，MDD的神经生物学尚未完全阐明；因此，可能涉及其他生化改变。谷氨酸能系统及其相关受体已被认为与MDD的病理生理学有关。事实上，N-甲基-D-天冬氨酸（NMDA）受体作为一种谷氨酸受体，是经典抗抑郁药和新型速效抗抑郁药的结合或调节位点。因此，本综述旨在呈现描述调节NMDA受体的抗抑郁药的作用以及促成抗抑郁反应的机制的证据。
